On Thursday, ResMed Inc (NYSE:RMD) reported that second-quarter fiscal 2026 adjusted earnings of 2.81, beating the consensus of $2.72.
Quarterly sales increased 11% year over year to $1.42 billion, surpassing the consensus estimate of $1.396 billion.
Sales increased 9% on a constant currency basis, driven by increased demand for our portfolio of sleep devices, masks, and accessories.
Residential Care Software revenue increased by 5% on a constant currency basis.
In December 2025, the U.S. Food and Drug Administration (FDA) cleared ResMed’s Personalized Therapy Comfort Settings (PTCS) to be marketed as Smart Comfort.
Smart Comfort is the first FDA-cleared AI-enabled medical device that recommends personalized comfort settings for obstructive sleep apnea (OSA) patients to start and stay on CPAP therapy.
Smart Comfort will launch in early 2026 in a limited U.S. beta version for new users of myAir, ResMed’s consumer sleep companion app, paired with a ResMed AirSense 11 …